TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36757696

Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride with fluoride varnish
Number of subjects: 2998

Group type: COMPARATOR
Intervention: Glass ionomer sealants with fluoride varnish
Number of subjects: 2998
Study: 36757706

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Consolidation chemotherapy (high-dose cytarabine)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Allogeneic HCT
Number of subjects: 143
Study: 36757755

Group type: EXPERIMENTAL
Intervention: Argatroban plus alteplase (n=402); intravenous argatroban (100 μg/kg bolus over 3-5 minutes followed by an infusion of 1.0 μg/kg per minute for 48 hours) within 1 hour after alteplase (0.9 mg/kg; maximum dose, 90 mg; 10% as 1-minute bolus, remaining infused over 1 hour)
Number of subjects: 808

Group type: COMPARATOR
Intervention: Alteplase alone (n=415)
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Argatroban plus alteplase
Number of subjects: 808

Group type: COMPARATOR
Intervention: Alteplase alone
Number of subjects: 808
Study: 36757770

Group type: EXPERIMENTAL
Intervention: MyPlate smartphone app
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 36757779

Group type: EXPERIMENTAL
Intervention: Nursing Home Severity Index-Pressure Injury with severity dimensions and Worst-Braden score
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Nursing Home Severity Index-Pressure Injury
Number of subjects: 1015
Study: 36757859

Group type: EXPERIMENTAL
Intervention: Leadless-VVI
Number of subjects: 9858

Group type: COMPARATOR
Intervention: Transvenous-VVI
Number of subjects: 9858
Study: 36758013

Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 4439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4439
Study: 36758420

Group type: EXPERIMENTAL
Intervention: farletuzumab + chemotherapy
Number of subjects: 214

Group type: COMPARATOR
Intervention: placebo + chemotherapy
Number of subjects: 214
Study: 36758570

Group type: EXPERIMENTAL
Intervention: Colesevelam (625 mg overencapsulated tablets, starting dose of two capsules twice daily for 12 days, titrated to effect during the first 5 days)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Colesevelam
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 36758572

Group type: EXPERIMENTAL
Intervention: BIF-A1
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: BIF-A2
Number of subjects: 399

Group type: COMPARATOR
Intervention: Degludec
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: BIF
Number of subjects: 399
Study: 36758612

Group type: EXPERIMENTAL
Intervention: Reperfusion (5.5% of patients)
Number of subjects: 5213

Group type: EXPERIMENTAL
Intervention: Parenteral anticoagulants (92.1% of patients)
Number of subjects: 5213

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (75.6% at discharge)
Number of subjects: 5213

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (6.7% at discharge)
Number of subjects: 5213
Study: 36758710

Group type: EXPERIMENTAL
Intervention: Prepregnancy lifestyle intervention (16 weeks)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Educational control
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Prepregnancy lifestyle intervention
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Prepregnancy weight loss (independent of group)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: ≥5% weight loss before conception (independent of group)
Number of subjects: 199
Study: 36758712

Group type: EXPERIMENTAL
Intervention: Speed of Processing Training (SOPT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 60
Study: 36758713

Group type: EXPERIMENTAL
Intervention: Tablet-based application with feedback, monitoring, and progression
Number of subjects: 663

Group type: COMPARATOR
Intervention: Evidence-based home exercise program on paper
Number of subjects: 663
Study: 36758740

Group type: EXPERIMENTAL
Intervention: Modified High-Intensity Interval Training (HIIT) - short bouts (≤ 90 seconds) at 80%-90% of peak oxygen consumption (VO2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT) - 20 minutes at 50%-60% of VO2
Number of subjects: 20
Study: 36758935

Group type: EXPERIMENTAL
Intervention: PE with PE Coach
Number of subjects: 124

Group type: COMPARATOR
Intervention: PE without PE Coach
Number of subjects: 124
Study: 36759013

Group type: EXPERIMENTAL
Intervention: Neoadjuvant sintilimab plus triplet chemotherapy (liposomal paclitaxel, cisplatin, and S-1) every 3 weeks for two cycles
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neoadjuvant sintilimab plus triplet chemotherapy
Number of subjects: 30
Study: 36759296

Group type: EXPERIMENTAL
Intervention: Interdisciplinary collaborative radiotherapy planning
Number of subjects: 37
Study: 36759316

Group type: EXPERIMENTAL
Intervention: PROMIS Physical Function
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: RMDQ
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Pain Behavior
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Pain Interference
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: PCS
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: FABQ
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: CPAQ
Number of subjects: 328
Study: 36759606

Group type: EXPERIMENTAL
Intervention: Corticospinal tract (CST) sparing
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Assessment strategies for muscle-specific motor recovery
Number of subjects: 748
Study: 36759673

Group type: EXPERIMENTAL
Intervention: T-VEC plus neoadjuvant chemotherapy (NAC)
Number of subjects: 37
Study: 36759706

Group type: EXPERIMENTAL
Intervention: NIPPV with rate settings multiplied by three
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: NIPPV with rate settings divided by three
Number of subjects: 50
Study: 36759720

Group type: EXPERIMENTAL
Intervention: Trabectedin/pegylated liposomal doxorubicin (TP) followed by platinum therapy at relapse
Number of subjects: 617

Group type: COMPARATOR
Intervention: Carboplatin/pegylated liposomal doxorubicin (CP)
Number of subjects: 617
Study: 36759766

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) program
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 36759788

Group type: EXPERIMENTAL
Intervention: Hypersensitivity pneumonitis patients with pulmonary hypertension (PH)
Number of subjects: 60
Study: 36759858

Group type: EXPERIMENTAL
Intervention: Smartphone application for remote monitoring
Number of subjects: 310

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 310
Study: 36759873

Group type: EXPERIMENTAL
Intervention: Supplementation with essential amino acids (EAA) and intermediates of the tricarboxylic acid (TCA) cycle (citrate, malate, succinate)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Supplementation with EAA and TCA intermediates
Number of subjects: 92
Study: 36759893

Group type: EXPERIMENTAL
Intervention: Usual care plus an AI-decision aid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 36759901

Group type: EXPERIMENTAL
Intervention: Intranasal infusion of neural stem cells (NSCs) with nasal patches and rehabilitation therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Rehabilitation therapy only
Number of subjects: 25
Study: 36759902

Group type: EXPERIMENTAL
Intervention: INTERCARE intervention with high fidelity score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: INTERCARE intervention with high fidelity to advance care planning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: INTERCARE intervention with low fidelity to communication tools (e.g., ISBAR)
Number of subjects: 0
Study: 36759915

Group type: EXPERIMENTAL
Intervention: Artificial intelligence-PCIT (AI-PCIT) group
Number of subjects: 100

Group type: COMPARATOR
Intervention: PCIT-sham biometric group (Control)
Number of subjects: 100
Study: 36760521

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate high-fat diet with exercise
Number of subjects: 57

Group type: COMPARATOR
Intervention: Low-carbohydrate high-fat diet without exercise
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Normal diet with exercise
Number of subjects: 57

Group type: COMPARATOR
Intervention: Normal diet without exercise
Number of subjects: 57
Study: 36760576

Group type: EXPERIMENTAL
Intervention: Patient-centered self-management intervention for eight weeks duration
Number of subjects: 612

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 612
Study: 36760605

Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: 0.6% compound lidocaine hydrochloride injection
Number of subjects: 164

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 164
Study: 36760785

Group type: EXPERIMENTAL
Intervention: EDL app
Number of subjects: 100

Group type: COMPARATOR
Intervention: Injury prevention text messages
Number of subjects: 100
Study: 36760794

Group type: EXPERIMENTAL
Intervention: rTMS/SS
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: rTMS/sham SS
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: sham rTMS/SS
Number of subjects: 36

Group type: COMPARATOR
Intervention: sham rTMS/Sham SS
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: S1 rTMS and SS alone or in combination
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of S1 rTMS and SS
Number of subjects: 36
Study: 36761135

Group type: EXPERIMENTAL
Intervention: Care as usual plus guided self-help stress management guide (Doing What Matters in Times of Stress, DWM) and a five-session cognitive behavioral intervention (Problem Management Plus, PM+)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Care as usual only
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Care as usual plus DWM and PM+
Number of subjects: 212
Study: 36761185

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 62
Study: 36761371

Group type: EXPERIMENTAL
Intervention: Physical activity recommendations met
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: High-risk physical activity profile
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Age 60-69 years
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Age 70-79 years
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Age 80+ years
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: BMI 30-39
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: BMI 40+
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Unemployment
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Retirement
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index score 1-2
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index score 3+
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 768
Study: 36761410

Group type: EXPERIMENTAL
Intervention: 16 weeks of moderate intensity aerobic exercise
Number of subjects: 136

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 136
Study: 36761900

Group type: EXPERIMENTAL
Intervention: Intranasal photodynamic therapy (PDT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 36761922

Group type: EXPERIMENTAL
Intervention: Artificial intelligence (AI) based algorithm using ECG signals collected through a non-invasive device.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-invasive wearable device for recording physiological data and respiratory rate.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep learning (DL) AI algorithm.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous pilot results based on four healthy adults.
Number of subjects: 0
Study: 36761980

Group type: EXPERIMENTAL
Intervention: Primary adenocarcinomas
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Primary squamous cell tumors
Number of subjects: 33
Study: 36762424

Group type: COMPARATOR
Intervention: Peak hsTnI <75 ng/L
Number of subjects: 4553

Group type: EXPERIMENTAL
Intervention: Peak hsTnI 75 ng/L to <1000 ng/L
Number of subjects: 4553

Group type: EXPERIMENTAL
Intervention: Peak hsTnI ≥1000 ng/L
Number of subjects: 4553

Group type: EXPERIMENTAL
Intervention: Peak hsTnI ≥75 ng/L
Number of subjects: 4553

Group type: EXPERIMENTAL
Intervention: Peak hsTnI ≥75 ng/L with ischemic features
Number of subjects: 4553

Group type: EXPERIMENTAL
Intervention: Peak hsTnI ≥75 ng/L without ischemic features
Number of subjects: 4553
Study: 36762782

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus for 6 months
Number of subjects: 18
Study: 36762851

Group type: EXPERIMENTAL
Intervention: Ide-cel
Number of subjects: 386

Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 386
Study: 36762852

Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 456

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 456
Study: 36762865

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy plus medical care
Number of subjects: 352

Group type: COMPARATOR
Intervention: Medical care alone
Number of subjects: 352
Study: 36762880

Group type: EXPERIMENTAL
Intervention: eDiagnoses (new medical computerized tool)
Number of subjects: 446

Group type: COMPARATOR
Intervention: medDiagnoses (standard clinical approach)
Number of subjects: 446
Study: 36762893

Group type: EXPERIMENTAL
Intervention: Pain and disability drivers management model
Number of subjects: 0
Study: 36762930

Group type: EXPERIMENTAL
Intervention: gp120-reactive monoclonal antibodies (mAbs) isolated from participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccine-induced gp120-specific antibody lineages
Number of subjects: 0
Study: 36763114

Group type: EXPERIMENTAL
Intervention: US-guided bilateral thoracic paravertebral blocks (TPVBs) in Group NO (BMI < 30)
Number of subjects: 82

Group type: COMPARATOR
Intervention: US-guided bilateral thoracic paravertebral blocks (TPVBs) in Group O (BMI ≥ 30)
Number of subjects: 82
Study: 36763159

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/day
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 36763183

Group type: EXPERIMENTAL
Intervention: 12-week web-based dietary intervention with daily text messages
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 50
Study: 36763243

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 569
Study: 36763307

Group type: EXPERIMENTAL
Intervention: Extended interval dosing (EID) of natalizumab (≤ 9 infusions/year)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Standard interval dosing (SID) of natalizumab (≥ 11 infusions/year)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Extended interval dosing (EID)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Standard interval dosing (SID)
Number of subjects: 303
Study: 36763328

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study: 36763327

Group type: EXPERIMENTAL
Intervention: Acoziborole (20-1200 mg single oral dose)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Activated charcoal (in additional cohorts)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Capsules versus tablets (in additional cohorts)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 960-mg tablet cohort (in additional cohorts)
Number of subjects: 128
Study: 36763359

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser therapy (CLT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham laser therapy (SLT)
Number of subjects: 72
Study: 36763358

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg
Number of subjects: 2046

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg
Number of subjects: 2046

Group type: COMPARATOR
Intervention: Enoxaparin (1 mg/kg subcutaneous twice daily)
Number of subjects: 2046
Study: 36763521

Group type: EXPERIMENTAL
Intervention: Balanced nonopioid general anesthesia with lidocaine
Number of subjects: 772

Group type: COMPARATOR
Intervention: Balanced opioid general anesthesia with sufentanil
Number of subjects: 772
Study: 36763537

Group type: EXPERIMENTAL
Intervention: KPd (carfilzomib 20/27 mg/m2, pomalidomide 4 mg, dexamethasone 40 mg)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Dara-KPd (KPd with daratumumab)
Number of subjects: 94
Study: 36763614

Group type: EXPERIMENTAL
Intervention: Tea Tree Oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coconut Oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36763627

Group type: EXPERIMENTAL
Intervention: Wearable device with UVR-sensing technology and mobile application notifications about exposure and prompts to use sunscreen.
Number of subjects: 386

Group type: COMPARATOR
Intervention: Control group received the device and a separate research mobile application without exposure information or notifications.
Number of subjects: 386
Study: 36763857

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall adverse events (AEs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crohn's disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutropenia
Number of subjects: 0
Study: 36763878

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 1303

Group type: COMPARATOR
Intervention: Baricitinib 2 mg
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: All-baricitinib (any dose)
Number of subjects: 1303
Study: 36763879

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg (continuous dosing)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg (downtitration)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Placebo (treatment withdrawal, 4-mg cohort)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg (continuous dosing)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Baricitinib 1 mg (downtitration)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Placebo (treatment withdrawal, 2-mg cohort)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg (downtitration)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Baricitinib 4 mg (treatment withdrawal)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Baricitinib 2 mg (treatment withdrawal)
Number of subjects: 526
Study: 36763899

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (ONA) injections (1.5 U/injection site)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline) injections
Number of subjects: 20
Study: 36763919

Group type: EXPERIMENTAL
Intervention: Intravaginal treatment with gel containing 600 IU/mL of oxytocin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (gel alone)
Number of subjects: 50
Study: 36763929

Group type: EXPERIMENTAL
Intervention: Escitalopram treatment
Number of subjects: 92
Study: 36763936

Group type: EXPERIMENTAL
Intervention: Encorafenib + Binimetinib + Cetuximab
Number of subjects: 95
Study: 36763945

Group type: EXPERIMENTAL
Intervention: Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide (B-DRC)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Dexamethasone-Rituximab-Cyclophosphamide (DRC)
Number of subjects: 204
Study: 36764101

Group type: EXPERIMENTAL
Intervention: Step training with rhythmic cuing
Number of subjects: 48
Study: 36764316

Group type: EXPERIMENTAL
Intervention: Sotorasib
Number of subjects: 345

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 345
Study: 36764323

Group type: EXPERIMENTAL
Intervention: CYAD-01 (autologous NKG2D-based CAR T-cell therapy)
Number of subjects: 16
Study: 36764326

Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg acute treatment (n=19)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg twice daily for 3 weeks (n=16)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo acute treatment (n=12)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo for 3 weeks (n=15)
Number of subjects: 35
Study: 36764513

Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA) defined as an apnea hypopnea index ≥ 15 events/h
Number of subjects: 1920

Group type: COMPARATOR
Intervention: No OSA (control group)
Number of subjects: 1920
Study: 36764628

Group type: EXPERIMENTAL
Intervention: OJ with 22g of oat bran containing 6g of β-glucan
Number of subjects: 0

Group type: COMPARATOR
Intervention: OJ without oat bran
Number of subjects: 0
Study: 36764664

Group type: EXPERIMENTAL
Intervention: ASCENT intervention (performance feedback report, webinar, staff and patient educational videos)
Number of subjects: 655

Group type: COMPARATOR
Intervention: Control (educational brochure)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: ASCENT intervention
Number of subjects: 655
Study: 36764680

Group type: EXPERIMENTAL
Intervention: Machine learning-directed care
Number of subjects: 59
Study: 36764712

Group type: EXPERIMENTAL
Intervention: 0.3 Gy/6 fractions of LDRT
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 3 Gy/6 fractions of LDRT
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 114
Study: 36764715

Group type: EXPERIMENTAL
Intervention: Multi-modality medical imaging (brain MRI, retinal fundus photograph, fundus OCT, ultrasonography of ICA) every 2-4 years
Number of subjects: 1000
Study: 36764718

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo SMT
Number of subjects: 100
Study: 36764835

Group type: EXPERIMENTAL
Intervention: Health-related text warning
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Sugar pictorial warning
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Health pictorial warning
Number of subjects: 961

Group type: COMPARATOR
Intervention: No-warning control
Number of subjects: 961
Study: 36764892

Group type: EXPERIMENTAL
Intervention: Abnormal stress CMR
Number of subjects: 2349

Group type: COMPARATOR
Intervention: Normal stress CMR
Number of subjects: 2349

Group type: COMPARATOR
Intervention: Invasive coronary angiography
Number of subjects: 2349

Group type: COMPARATOR
Intervention: Downstream costs
Number of subjects: 2349
Study: 36764917

Group type: EXPERIMENTAL
Intervention: ICE-guided LAAC with the Watchman FLX device
Number of subjects: 100
Study: 36764966

Group type: EXPERIMENTAL
Intervention: Secretin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0